United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - floxuridine (unii: 039lu44i5m) (floxuridine - unii:039lu44i5m) - floxuridine 100 mg in 1 ml - floxuridine for injection, usp is effective in the palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. patients with known disease extending beyond an area capable of infusion via a single artery should, except in unusual circumstances, be considered for systemic therapy with other chemotherapeutic agents. floxuridine therapy is contraindicated for patients in a poor nutritional state, those with depressed bone marrow function or those with potentially serious infections.

United States - English - NLM (National Library of Medicine)

cerona therapeutics, inc. - floxuridine (unii: 039lu44i5m) (floxuridine - unii:039lu44i5m) - floxuridine for injection, usp is effective in the palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. patients with known disease extending beyond an area capable of infusion via a single artery should, except in unusual circumstances, be considered for systemic therapy with other chemotherapeutic agents. floxuridine therapy is contraindicated for patients in a poor nutritional state, those with depressed bone marrow function or those with potentially serious infections.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - floxuridine (unii: 039lu44i5m) (floxuridine - unii:039lu44i5m) - floxuridine 500 mg in 5 ml - floxuridine for injection, usp is effective in the palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means.  patients with known disease extending beyond an area capable of infusion via a single artery should, except in unusual circumstances, be considered for systemic therapy with other chemotherapeutic agents. floxuridine therapy is contraindicated for patients in a poor nutritional state, those with depressed bone marrow function or those with potentially serious infections.

United States - English - NLM (National Library of Medicine)

cardinal health - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine 500 mg

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - allopurinol sodium (unii: 428673rc2z) (allopurinol - unii:63cz7gjn5i) - allopurinol 500 mg in 25 ml - allopurinol sodium for injection is indicated for the management of adult and pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy. allopurinol sodium for injection is contraindicated in patients with a history of severe reaction to any formulation of allopurinol. based on findings in animals, allopurinol sodium for injection may cause fetal harm when administered to a pregnant woman. adverse developmental outcomes have been described in exposed animals (see data) . allopurinol and its metabolite oxypurinol have been shown to cross the placenta following administration of maternal allopurinol. available limited published data on allopurinol use in pregnant women do not demonstrate a clear pattern or increase in frequency of adverse developmental outcomes. among approximately 50 pregnancies described in published literature, 2 infants with major congenital malf

United States - English - NLM (National Library of Medicine)

cameron pharmaceuticals, llc - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine 250 mg - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules (see microbiology ). flucytosine capsules are contraindicated in patients with a known hypersensitivity to the drug. flucytosine capsules are contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings ).

United States - English - NLM (National Library of Medicine)

mylan institutional llc - allopurinol sodium (unii: 428673rc2z) (allopurinol - unii:63cz7gjn5i) - allopurinol 500 mg in 25 ml - aloprim is indicated for the management of adult and pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy. aloprim is contraindicated in patients with a history of severe reaction to any formulation of allopurinol. based on findings in animals, aloprim may cause fetal harm when administered to a pregnant woman. adverse developmental outcomes have been described in exposed animals (see data) . allopurinol and its metabolite oxypurinol have been shown to cross the placenta following administration of maternal allopurinol. available limited published data on allopurinol use in pregnant women do not demonstrate a clear pattern or increase in frequency of adverse developmental outcomes. among approximately 50 pregnancies described in published literature, 2 infants with major congenital malformations have been reported with following maternal allopurinol exposure.

United States - English - NLM (National Library of Medicine)

bausch health us llc - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine 250 mg - ancobon is indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. ancobon should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to ancobon (see microbiology ). ancobon is contraindicated in patients with a known hypersensitivity to the drug. ancobon is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings).

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine 250 mg

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine 250 mg - flucytosine is indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine (see microbiology) . flucytosine is contraindicated in patients with a known hypersensitivity to the drug. flucytosine is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings ).